17β-Dihydroequilin
Pharmacodynamics

17β-Dihydroequilin

Section Title: Pharmacodynamics
Table Section Text: None

Compound	Synonym	Proportion (%)	Relative potency in the vagina (%)	Relative potency in the uterus (%)	RBA for ERα (%)	RBA for ERβ (%)	ERα / ERβ RBA ratio

Conjugated estrogens	–	100	38	100	–	–	–

Estrone	–	49.1–61.5	30	32	26	52	0.50

Equilin	Δ7-Estrone	22.4–30.5	42	80	13	49	0.26

17α-Dihydroequilin	Δ7-17α-Estradiol	13.5–19.5	0.06	2.6	41	32	1.30

17α-Estradiol	–	2.5–9.5	0.11	3.5	19	42	0.45

Δ8-Estrone	–	3.5–3.9	?	?	19	32	0.60

Equilenin	Δ6,8-Estrone	2.2–2.8	1.3	11.4	15	20–29	0.50–0.75

17β-Dihydroequilin	Δ7-17β-Estradiol	0.5–4.0	83	200	113	108	1.05

17α-Dihydroequilenin	Δ6,8-17α-Estradiol	1.2–1.6	0.018	1.3	20	49	0.40

17β-Estradiol	–	0.56–0.9	100	?	100	100	1.00

17β-Dihydroequilenin	Δ6,8-17β-Estradiol	0.5–0.7	0.21	9.4	68	90	0.75

Δ8-17β-Estradiol	–	Small amounts	?	?	68	72	0.94

Notes: All listed compounds are present in CEE products specifically in the form of the sodium salts of the sulfate esters (i.e., as sodium estrone sulfate, sodium equilin sulfate, etc.).

Sentence(s)

In terms of relative binding affinity for the ERs, 17β-dihydroequilin has 113% and 108% of ERα and ERβ.

final_sentence: In terms of relative binding affinity for the ERs, 17β-dihydroequilin has 113% and 108% of ERα and ERβ.